
Please try another search
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Robert Tjian | 72 | 2016 | Chairman of Scientific Advisory Board |
Arthur T. Sands | 59 | 2014 | CEO, President & Director |
Julia Paige Gregory | 72 | 2019 | Independent Chairman |
Edward C. Saltzman | 70 | 2022 | Independent Director |
David L. Lacey | 73 | 2016 | Independent Director |
Ronald Levy | - | 2023 | Member of Medical Advisory Board |
Lori Anne Kunkel | 67 | 2019 | Independent Director |
Paul M. Silva | 59 | 2021 | Independent Director |
Judith A. Reinsdorf | 61 | 2021 | Independent Director |
Roy D. Baynes | 70 | 2025 | Independent Director |
Anil Kapur | 54 | 2024 | Independent Director |
John Kuriyan | - | - | Founder & Member of Scientific Advisory Board |
Arthur Weiss | - | - | Founder & Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review